Sudarshan Pharma Industries Ltd Faces Bearish Momentum Amid Technical Downturn

Price Movement and Market Context

On 7 January 2026, Sudarshan Pharma closed at ₹25.01, down 4.69% from the previous close of ₹26.24. The intraday range was between ₹24.70 and ₹26.00, reflecting heightened volatility. The stock remains significantly below its 52-week high of ₹53.50, underscoring a steep decline over the past year. The 52-week low stands at ₹21.62, indicating that the current price is closer to the lower end of its annual range.

Comparatively, Sudarshan Pharma’s returns have lagged the broader Sensex benchmark across multiple timeframes. Over the past week, the stock declined by 10.13%, while the Sensex gained 0.46%. The one-month return for the stock was -5.37%, against the Sensex’s -0.76%. Year-to-date, Sudarshan Pharma has fallen 9.22%, whereas the Sensex is marginally down by 0.18%. Most strikingly, the stock has plummeted 51.01% over the last year, in stark contrast to the Sensex’s 9.10% gain. This underperformance highlights the stock’s vulnerability amid sectoral and company-specific headwinds.

Technical Trend Shift: From Mildly Bearish to Bearish

The technical trend for Sudarshan Pharma has shifted from mildly bearish to outright bearish, signalling increased downside risk. Daily moving averages have turned decisively bearish, with the stock trading below its key short-term and medium-term averages. This downward crossover typically indicates that sellers are gaining control, and the momentum is skewed towards further declines.

On the weekly chart, the Moving Average Convergence Divergence (MACD) remains mildly bullish, suggesting some underlying positive momentum in the medium term. However, the monthly MACD has deteriorated to mildly bearish, reflecting weakening momentum over a longer horizon. This divergence between weekly and monthly MACD readings points to a complex technical picture, where short-term relief rallies may occur but the broader trend remains negative.

Momentum Oscillators and Volatility Indicators

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in neutral territory. This lack of directional momentum from RSI suggests the stock is neither oversold nor overbought, leaving room for further downside or sideways consolidation.

Bollinger Bands on weekly and monthly charts are firmly bearish, with the price hugging the lower band. This positioning indicates sustained selling pressure and heightened volatility. The contraction and expansion of these bands in recent weeks have signalled increased uncertainty among traders.

Additional Technical Signals

The Know Sure Thing (KST) indicator on the weekly timeframe remains mildly bullish, hinting at some short-term positive momentum. However, the monthly KST is inconclusive, providing no clear directional bias. Dow Theory analysis on the weekly chart also shows mild bullishness, but the monthly trend is flat, indicating no definitive long-term trend.

On balance, the technical indicators present a mixed but predominantly bearish outlook, with short-term oscillators offering limited relief against a backdrop of weakening moving averages and volatility measures.

Mojo Score and Market Capitalisation Assessment

Sudarshan Pharma holds a Mojo Score of 37.0, categorised as a Sell rating. This score reflects the combined assessment of technical, fundamental, and market sentiment factors, signalling caution for investors. The company’s market cap grade is 4, indicating a mid-sized market capitalisation relative to its peers in the specialty chemicals sector.

The downgrade to a Sell rating from a previously ungraded status underscores the deteriorating outlook. Investors should weigh this against the company’s operational fundamentals and sector dynamics before making allocation decisions.

Sectoral and Industry Context

Operating within the specialty chemicals industry, Sudarshan Pharma faces sector-specific challenges including raw material cost volatility, regulatory pressures, and competitive intensity. The sector has seen mixed performance recently, with some companies benefiting from niche product demand while others grapple with margin compression.

Given Sudarshan Pharma’s technical weakness and underperformance relative to the Sensex, investors may prefer to consider alternative specialty chemical stocks with stronger momentum and more favourable technical profiles.

Investor Takeaway and Outlook

Technically, Sudarshan Pharma is exhibiting clear signs of bearish momentum with daily moving averages confirming a downtrend and monthly MACD reinforcing longer-term weakness. The absence of strong RSI signals suggests the stock has not yet reached oversold extremes, implying potential for further declines or prolonged consolidation near current levels.

Investors should exercise caution and monitor key support levels around ₹21.62, the 52-week low, which may act as a critical floor. A sustained break below this level could trigger accelerated selling pressure. Conversely, any recovery attempts will need to overcome resistance near the 20-day and 50-day moving averages, currently trending lower.

Given the stock’s underperformance relative to the Sensex and the specialty chemicals sector, alongside a Sell Mojo Grade, a defensive stance is advisable. Investors seeking exposure to this sector might consider stocks with stronger technical setups and more robust momentum indicators.

In summary, Sudarshan Pharma’s technical parameters have shifted decisively towards bearishness, reflecting a challenging environment for the stock. While short-term oscillators offer limited bullish hints, the prevailing trend and momentum indicators counsel prudence.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →